Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.

Oelgarth N, Martin K, Junker F, Serger C, Herr C, Buchi M, Gremlich L, Fusi I, Fürst J, Herzig P, Moosmann P, Heinzelmann-Schwarz V, Mertz KD, Rosenberg R, Schaeuble K, Carralot JP, Luu TT, Kreft B, Pattabiraman V, Zippelius A

Open source

DOI: 10.1136/jitc-2026-015090
Published: 2026 Jul 14
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2026-015090,
  title = {Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.},
  author = {Oelgarth N and Martin K and Junker F and Serger C and Herr C and Buchi M and Gremlich L and Fusi I and Fürst J and Herzig P and Moosmann P and Heinzelmann-Schwarz V and Mertz KD and Rosenberg R and Schaeuble K and Carralot JP and Luu TT and Kreft B and Pattabiraman V and Zippelius A},
  year = {2026},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2026-015090},
  url = {https://doi.org/10.1136/jitc-2026-015090}
}

RIS

TY  - JOUR
TI  - Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.
AU  - Oelgarth N
AU  - Martin K
AU  - Junker F
AU  - Serger C
AU  - Herr C
AU  - Buchi M
AU  - Gremlich L
AU  - Fusi I
AU  - Fürst J
AU  - Herzig P
AU  - Moosmann P
AU  - Heinzelmann-Schwarz V
AU  - Mertz KD
AU  - Rosenberg R
AU  - Schaeuble K
AU  - Carralot JP
AU  - Luu TT
AU  - Kreft B
AU  - Pattabiraman V
AU  - Zippelius A
PY  - 2026
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2026-015090
UR  - https://doi.org/10.1136/jitc-2026-015090
ER  -

APA

N, O., K, M., F, J., C, S., C, H., M, B., L, G., I, F., J, F., P, H., P, M., V, H., KD, M., R, R., K, S., JP, C., TT, L., B, K., V, P., & A, Z. (2026). Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-015090

Source records

pubmed · retrieved 2026-09-26T17:57:42.335Z